IDEXX Laboratories Inc (IDXX)

Currency in USD
651.16
-6.90(-1.05%)
Real-time Data·
IDXX Scorecard
Full Analysis
Management has been aggressively buying back shares
IDXX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
646.68664.71
52 wk Range
356.14688.12
Key Statistics
Prev. Close
658.06
Open
662
Day's Range
646.68-664.71
52 wk Range
356.14-688.12
Volume
219.66K
Average Volume (3m)
608.7K
1-Year Change
36.29%
Book Value / Share
18.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IDXX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
673.91
Upside
+3.49%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

IDEXX Laboratories Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

IDEXX Laboratories Inc Company Profile

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories Inc SWOT Analysis


Market Leadership
Explore IDEXX's dominance in veterinary diagnostics, balancing declining visits with increased utilization and innovative product launches
Financial Resilience
Despite market headwinds, IDEXX maintains robust profitability with a 60.7% gross margin and 7.2% revenue growth, showcasing its financial strength
Growth Projections
Analysts forecast sustainable double-digit top-line growth for IDEXX, with price targets ranging from $481 to $630, reflecting optimistic long-term outlook
Strategic Innovation
Delve into IDEXX's product development strategy, including the inVue Dx Analyzer and IDXX Cancer Dx, driving competitive advantage in a evolving market
Read full SWOT analysis

IDEXX Laboratories Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $3.63 beat forecasts by 10.33%, revenue reached $1.11B, up 11% YoY
  • Stock surged 22.6% to $640.86 in pre-market trading following strong earnings report
  • Full-year revenue guidance raised to $4.205B-$4.280B, EPS outlook increased to $12.40-$12.76
  • Strong performance driven by innovation in diagnostics and international expansion plans
  • CEO highlights rising pet owner expectations and IDEXX's position to support care objectives
Last Updated: 04/08/2025, 14:42
Read Full Transcript

Compare IDXX to Peers and Sector

Metrics to compare
IDXX
Peers
Sector
Relationship
P/E Ratio
53.3x−3.8x−0.5x
PEG Ratio
2.79−0.100.00
Price/Book
36.0x2.2x2.6x
Price / LTM Sales
13.0x3.7x3.3x
Upside (Analyst Target)
6.4%30.0%43.3%
Fair Value Upside
Unlock−0.4%6.9%Unlock

Analyst Ratings

7 Buy
5 Hold
1 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 673.91
(+3.49% Upside)

Earnings

Latest Release
Aug 04, 2025
EPS / Forecast
3.63 / 3.29
Revenue / Forecast
1.11B / 1.06B
EPS Revisions
Last 90 days

IDXX Income Statement

People Also Watch

833.31
AXON
-1.09%
186.86
LULU
-1.36%
184.85
TXN
-1.27%
350.09
CDNS
-0.56%
138.92
ANET
-0.19%

FAQ

What Stock Exchange Does IDEXX Labs Trade On?

IDEXX Labs is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for IDEXX Labs?

The stock symbol for IDEXX Labs is "IDXX."

What Is the IDEXX Labs Market Cap?

As of today, IDEXX Labs market cap is 52.20B.

What Is IDEXX Labs's Earnings Per Share (TTM)?

The IDEXX Labs EPS (TTM) is 12.10.

When Is the Next IDEXX Labs Earnings Date?

IDEXX Labs will release its next earnings report on 03 Nov 2025.

From a Technical Analysis Perspective, Is IDXX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has IDEXX Labs Stock Split?

IDEXX Labs has split 4 times.

How Many Employees Does IDEXX Labs Have?

IDEXX Labs has 11000 employees.

What is the current trading status of IDEXX Labs (IDXX)?

As of 11 Aug 2025, IDEXX Labs (IDXX) is trading at a price of 651.16, with a previous close of 658.06. The stock has fluctuated within a day range of 646.68 to 664.71, while its 52-week range spans from 356.14 to 688.12.

What Is IDEXX Labs (IDXX) Price Target According to Analysts?

The average 12-month price target for IDEXX Labs is USD673.90909, with a high estimate of USD785 and a low estimate of USD420. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +3.49% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.